Fairmount Funds Management LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001802528
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 12 positions · Total reported value $1.51B · Top-10 concentration 97.6% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 15.4% · 1 new · 0 cut · 1 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +31.7% · vs SPY +16.9% · Prev Value $1.38B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Fairmount Funds Management LLC disclosed 12 equity positions with a combined reported value of $1.51B. The filing implies a focused portfolio: its ten largest positions account for 97.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt.
The largest disclosed positions as of Q2 2026 were ORKA ($352.63M), DNTH ($247.33M), DMRA ($226.63M). By sector, the heaviest allocations are Health Care 96.2%, Other 3.8%. Versus the prior quarter, allocation shifted toward Other (+2.0pp) and away from Health Care (-2.0pp).
Versus the prior quarter, Fairmount Funds Management LLC opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 15.4% of positions. The portfolio's overlap with the prior quarter was 85% of names.
The largest new positions opened in Q2 2026 were FTH ($18.05M).
Of the 1 positions fully exited versus the prior quarter, the largest were SYRE ($202.67M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- FTH FAETH THERAPEUTICS INC · $18.05M
Fully Exited (vs previous quarter)
- SYRE SPYRE THERAPEUTICS INC · prev qtr: $202.67M
Insider Transactions (Form 4)
Latest Fairmount Funds Management LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-03 | D | Apogee Therapeutics, Inc. | 51,166 | — | SEC filing |
| 2026-09-03 | D | Apogee Therapeutics, Inc. | 340,855 | — | SEC filing |
| 2026-08-07 | Opt exercise | Apogee Therapeutics, Inc. | 10,370 | $43.85 | SEC filing |
| 2026-08-07 | Opt exercise | Apogee Therapeutics, Inc. | 31,838 | $17.00 | SEC filing |
| 2026-07-16 | Buy | CRESCENT BIOPHARMA, INC. | 853,450 | $14.50 | SEC filing |
| 2026-07-01 | Sell | Oruka Therapeutics, Inc. | 3,553,410 | $84.43 | SEC filing |
| 2026-07-01 | Conversion | Oruka Therapeutics, Inc. | 3,553,410 | — | SEC filing |
| 2026-06-23 | Sell | Spyre Therapeutics, Inc. | 4,684,781 | $85.31 | SEC filing |
Fund Profile
Fairmount Funds Management LLC, based in West Conshohocken, PA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 12 positions worth $1.51B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: WEST CONSHOHOCKEN, PA, United States
- SEC registration: 801-116848 (status: Approved), registered 2019-06-27
- Regulatory AUM (Form ADV): $5.80B as of 2026-08-07
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 6 private funds, of which 1 hedge funds
- Website: fairmountfunds.com
Portfolio Structure
- 12 positions · $1.51B reported value (Q2 2026)
- Top 10 holdings = 97.6% of reported value
- Largest position: ORKA (ORUKA THERAPEUTICS INC) at 23.3%
- Average position size: $126.08M
Sector Tilt
- Health Care 96.2%
- (classified holdings cover 96% of value)
Quarterly Activity
- Q2 2026: 1 new, 1 added, 1 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.71M | $352.63M | 23.31% | Hold | |
| 2 |
|
2.54M | $247.33M | 16.35% | Hold | |
| 3 |
|
8.71M | $226.63M | 14.98% | Hold | |
| 4 |
|
5.50M | $212.98M | 14.08% | Hold | |
| 5 |
|
4.55M | $101.18M | 6.69% | Hold | |
| 6 |
|
1.86M | $94.17M | 6.22% | Hold | |
| 7 |
|
5.09M | $93.52M | 6.18% | Add | |
| 8 |
|
2.36M | $59.87M | 3.96% | Hold | |
| 9 |
|
2.75M | $49.46M | 3.27% | Hold | |
| 10 |
|
298.65K | $39.64M | 2.62% | Hold | |
| 11 |
|
722.02K | $18.05M | 1.19% | New | |
| 12 |
|
8.62M | $17.51M | 1.16% | Hold | |
FAQ
What did Fairmount Funds Management LLC buy in 2026-Q2?
In its 2026-Q2 13F filing, Fairmount Funds Management LLC reported 12 equity positions worth $1.51B in aggregate; its largest disclosed positions were ORKA ($352.63M), DNTH ($247.33M), DMRA ($226.63M).
How large is Fairmount Funds Management LLC's portfolio?
Fairmount Funds Management LLC reported $1.51B of long equity holdings across 12 positions as of 2026-Q2. Top-10 holdings account for 97.6% of reported value.
What is Fairmount Funds Management LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.